MINT-IRBESARTAN/HCTZ TABLET

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

IRBESARTAN; HYDROCHLOROTHIAZIDE

Disponível em:

MINT PHARMACEUTICALS INC

Código ATC:

C09DA04

DCI (Denominação Comum Internacional):

IRBESARTAN AND DIURETICS

Dosagem:

150MG; 12.5MG

Forma farmacêutica:

TABLET

Composição:

IRBESARTAN 150MG; HYDROCHLOROTHIAZIDE 12.5MG

Via de administração:

ORAL

Unidades em pacote:

30/100/1000

Tipo de prescrição:

Prescription

Área terapêutica:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Resumo do produto:

Active ingredient group (AIG) number: 0240086001; AHFS:

Status de autorização:

CANCELLED POST MARKET

Data de autorização:

2020-07-08

Características técnicas

PRODUCT MONOGRAPH
Pr
MINT-IRBESARTAN/HCTZ
(Irbesartan and hydrochlorothiazide Tablets)
150/12.5 mg, 300/12.5 mg and 300/25 mg Tablets
House Standard
Angiotensin II AT
1
Receptor Blocker / Diuretic
Mint Pharmaceuticals Inc.
Date of Revision:
1093 Meyerside Drive, Unit 1
August 26, 2019
Mississauga, Ontario
L5T 1J6
CONTROL NO.: 230635
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
9
DRUG INTERACTIONS
...............................................................................................................
14
DOSAGE AND ADMINISTRATION
...........................................................................................
20
OVERDOSAGE
.............................................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
22
STORAGE AND STABILITY
......................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................... 26
PART II: SCIENTIFIC INFORMATION
....................................................................................
27
PHARMACEUTICAL INFORMATION
...............................................................................